Diurnal has created a pipeline of enhanced product opportunities within the endocrine area, where current therapies are considered to be sub-optimal and could be superseded with more effective physiological hormonal replacement products.

  • Chronocort®: our goal is to develop a first-in-class hydrocortisone product for the lifelong treatment of congenital adrenal hyperplasia and adrenal insufficiency
  • Alkindi®: a paediatric hydrocortisone replacement product authorised in the EU
  • Native Oral Testosterone: our objective is to create a native oral testosterone treatment for hypogonadism
  • T3 Modified Release: our target is to develop a modified release formulation for patients with hypothyroidism
  • siRNA: our target is to develop a novel therapy for Cushings